Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). (Q47763723)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Liliana Devizzi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Carmelo Carlo-Stella

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

F Botta

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

M A Gianni

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

E Bombardieri

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

20 May 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

number of pages

13

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

36

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1745-1757

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

https://scigraph.springernature.com/pub.10.1007/s00259-009-1141-x

0 references

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-009-1141-X

21 January 2018

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-rate effects in targeted radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Internal radionuclide therapy: the ULMDOS software for treatment planning

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance of normal tissue to therapeutic irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIRDOSE: personal computer software for internal dose assessment in nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absolute organ activity estimated by five different methods of background correction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19455328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-009-1141-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19455328%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47763723&oldid=1807443527"